Printer Friendly

VIROLOGY TESTING SCIENCES, INC. ANNOUNCES NEW HIV-2 CONFIRMATION AND SCREENING TEST

 HOUSTON and SOUTHAMPTON, N.Y., Jan. 4 /PRNewswire/ -- Virology Testing Sciences, Inc. (AMEX: VTS), announced today that its wholly owned subsidiary, Viral Testing Systems, Inc., has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its Fluorognost HIV-2 immunofluorescence assay (IFA) test for the detection of antibodies to Human Immunodeficiency Virus Type 2 (HIV-2).
 VTS said that the HIV-2 confirmation test has assumed greater importance due to the fact that the blood supply is now being screened for the HIV-2 virus, but there is no FDA approved confirmation test available.
 The VTS Fluorognost HIV-2 test now under review is an immunofluorescence assay embodying the same technology used by Fluorognost HIV-1, the recently FDA approved confirmatory and screening test for the detection of antibodies of Human Immunodeficiency Virus Type I.
 After the FDA's review of the IND submission, VTS anticipates approval by the middle of February to start clinical trials. The U.S. clinical trial will be conducted by the American Red Cross in Washington; South Florida Blood Center in Miami; Serologicals, Inc., in Georgia; and the Minneapolis State Laboratory.
 -0- 1/4/93
 /CONTACT: Holly G. Vaughan of VTS, 713-228-1544/
 (VTS)


CO: Virology Testing Sciences, Inc.; Viral Testing Systems, Inc. ST: Texas, New York IN: MTC SU: PDT

GK-KW -- NY056 -- 1348 01/04/93 13:37 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 4, 1993
Words:225
Previous Article:VIRGINIA PORT AUTHORITY $20 MILLION BONDS RATED 'AA' BY FITCH -- FITCH FINANCIAL WIRE --
Next Article:LONDON'S FARM DAIRY ANNOUNCES DEATH OF ITS PRESIDENT
Topics:


Related Articles
TELECONCEPTS SAYS AIDS TEST MAY IDENTIFY NEW HIV STRAIN
THERMASCAN STATEMENT ON UNRESOLVED HIV-1 ANTIBODY STATUS
THERMASCAN STOCKHOLDERS APPROVE MERGER WITH TELECONCEPTS
TELECONCEPTS COMPLETES ACQUISITION OF RIGHTS TO MARKET FDA-APPROVED CONFIRMATION AND SCREENING TEST FOR AIDS
VIROLOGY TESTING SCIENCES AGREES TO ACQUIRE THERMASCAN
VIRAL TESTING SYSTEMS WILL FOCUS ON THE ONLY FDA APPROVED TEST THAT CAN BOTH SCREEN AND CONFIRM FOR HIV
VIRAL TESTING SYSTEMS WILL FOCUS ON THE ONLY FDA APPROVED TEST THAT CAN BOTH SCREEN AND CONFIRM FOR HIV; DR. HERMANN MUCKE WILL HEAD R&D
Pittsburgh Firm Prepares to Set the Standard in Rapid HIV Testing.
SANOCHEMIA USA: Operating Activities Commence and HIV-2.
SANOCHEMIA USA: Operating Activities Commence and HIV-2.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters